Ben Middelkamp
Ben Middelkamp is a communications manager for the Department of Neurology, Department of Neurological Surgery and Stark Neurosciences Research Institute at Indiana University School of Medicine. Before joining the Office of Strategic Communications in December 2019, Ben spent nearly six years as a newspaper reporter in two Indiana cities. He earned a bachelor’s degree in Convergent Journalism from Indiana Wesleyan University in 2014. Ben enjoys translating his background in journalism to the communications and marketing needs of the school and its physicians and researchers.
Showing results for Ben Middelkamp
IU School of Medicine enrolls 100th patient in 23-site brain tumor radiation therapy clinical trial
Indiana University School of Medicine is one of 23 institutions in the Radiation One and Done Study (ROADS) clinical trial, and the university, in conjunction with its health partner Indiana University Health, enrolled the 100th patient in the study, according to the trial’s sponsor, GT Medical Technologies, Inc.
Ben Middelkamp | May 02, 2024
Graduate and medical students form science policy and communication group focused on Alzheimer's disease research
Ben Middelkamp | Apr 08, 2024
Alzheimer's disease researcher awarded Rainwater Charitable Foundation early-career scientist prize
Cristian Lasagna-Reeves, PhD received the prestigious 2024 Rainwater Prize for Innovative Early-Career Scientist. Lasagna-Reeves was presented the award at the Alzheimer’s Association’s Tau2024 Global Conference on March 25, 2024 in Washington, D.C.
Ben Middelkamp | Mar 28, 2024
Medical Neuroscience Graduate Organization educating about ocular health for April 8 solar eclipse
Ben Middelkamp | Mar 25, 2024
Nation's largest early-onset Alzheimer's study drives diversity
Ben Middelkamp | Mar 13, 2024
Reprogramming cell in adult central nervous system promotes regeneration of motor function axons after spinal cord injury
Ben Middelkamp | Mar 06, 2024
Neuroscientists receive NIH grants to investigate brain’s role in addiction, anxiety and obesity
Three Indiana University School of Medicine researchers each received National Institutes of Health grant funding to study under-explored mechanisms and connections in the brain using animal models. Through their investigations, they hope to discover therapeutic targets to treat health conditions, including obesity, anxiety and alcohol use disorder. The faculty investigators are members of the addiction research interest group at Stark Neurosciences Research Institute.
Ben Middelkamp | Jan 30, 2024
Glaucoma research program growing at IU School of Medicine
Ben Middelkamp | Jan 22, 2024
Neurologists at IU administer first-of-its-kind FDA-approved gene therapy
Neurologists at Indiana University School of Medicine are among the first clinicians in the nation to administer a groundbreaking gene-based therapy for patients living with a rare form of amyotrophic lateral sclerosis (ALS).
Ben Middelkamp | Jan 05, 2024
IU administering, leading clinical research on FDA-approved Alzheimer’s drug
For nearly a decade, lecanemab has been tested in clinical trials at IU School of Medicine—the newly FDA-approved drug is now being administered to patient at IU Health. The drug targets the removal of amyloid plaques in the brain—a hallmark of Alzheimer’s disease.
Ben Middelkamp | Nov 13, 2023